PCSA Stock Analysis: Buy, Sell, or Hold?
PCSA - Processa Pharmaceuticals, Inc. Common
$2.08
0.23 (12.43%)
â˛
5d:
+1.46%
30d:
-18.75%
90d:
-12.24%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When PCSA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PCSA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PCSA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: PCSA is currently trading at $2.08, which is considered slightly low relative to its 30-day fair value range of $2.00 to $2.41.
Technical Outlook: Technically, PCSA is in a downtrend. Immediate support is located at $1.82, while resistance sits at $2.18. The stock is showing strong short-term momentum, up 12.4% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $25.00 (+1101.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PCSA is in a downtrend. Immediate support is located at $1.82, while resistance sits at $2.18. The stock is showing strong short-term momentum, up 12.4% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $25.00 (+1101.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.00 -
$2.41
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+12.4%)
- BULLISH: Trading 1101.9% below Wall St target ($25.00)
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.00 -
$2.41
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.82
Resistance Level
$2.18
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.55
Wall Street Target
$25.00
(+1101.9%)
Share & Embed Analysis
Last updated: September 13, 2026 10:06 AM ET
Data refreshes hourly during market hours. Next update: 11:06 AM
Data refreshes hourly during market hours. Next update: 11:06 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCSA showing a specific setup today?
Insider Activity (6 Months)
12
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David Young
BUY
1545 shares
2026-04-15
George K Ng
BUY
1843 shares
2026-04-15
Russell Skibsted
BUY
1984 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
